KDR and thyroid gland carcinoma: These compounds show activity against several receptor tyrosine kinases (RTKs), some involved in the pathogenesis of thyroid cancer (i.e., BRAF, RAS, RET) and others in the vascular angiogenic pathway (i.e., VEGFR2, platelet-derived growth factor (PDGFR)).